← Back to headlines
GSK Acquires Nuvalent for $11 Billion to Boost Cancer Pipeline
Pharmaceutical giant GSK has announced an $11 billion acquisition of Nuvalent, a move aimed at significantly strengthening its pipeline of cancer treatment drugs and expanding its oncology portfolio.
9 Jun, 09:28 — 9 Jun, 09:28
Sources
Showing 1 of 1 sources
